This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/drugbank/drug/DB09006/identifier/wikipedia/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB09006/identifier/kegg-drug/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/drug/DB09006/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://www.drugs.com/international/

Statements

Subject Item
n2:DB09006
rdf:type
n3:Drug
n3:description
Clinofibrate is a fibrate drug sold and marketed in Japan.
n3:group
approved
owl:sameAs
n9:DB09006
dcterms:title
Clinofibrate
adms:identifier
n6:Clinofibrate n10:DB09006 n11:D01300
n3:synthesisReference
U.S. Patent 3,716,583.
foaf:page
n13:clinofibrate.html
n3:IUPAC-Name
n4:271B6433-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6439-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6438-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6435-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6436-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6437-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6431-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B642F-363D-11E5-9242-09173F13E4C5 n4:271B6432-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6430-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B643F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6440-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B643A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B643B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B643D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B643C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B643E-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
30299-08-2
n3:Bioavailability
n4:271B6445-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6447-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6448-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6449-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6444-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6443-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6446-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6434-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6441-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6442-363D-11E5-9242-09173F13E4C5